In vitro and in vivo models for the study of oral delivery of nanoparticles

Advanced Drug Delivery Reviews

Volumn 65, Issue 6, 2013, Pages 800-810

  Gamboa, Jennifer M ^a   Leong, Kam W ^a  

^a Duke University   (United States)

Author keywords

CaCo 2; Closed loop; Epithelium; Gut on a chip; Nanoparticles; Oral delivery; Oral delivery barriers; Simulated intestinal fluid; Transwell

Indexed keywords

CACO-2; CLOSED LOOPS; EPITHELIUM; GUT-ON-A-CHIP; INTESTINAL FLUID; ORAL DELIVERY;

DIFFUSION IN LIQUIDS; ENDOTHELIAL CELLS; MONOLAYERS;

NANOPARTICLES;

ALGINIC ACID; BETA GALACTOSIDASE; BIOLOGICAL PRODUCT; BLOOD CLOTTING FACTOR 8; CHITOSAN; DRUG; EUDRAGIT; HYDROXYPROPYLMETHYLCELLULOSE ACETATE SUCCINATE; HYDROXYPROPYLMETHYLCELLULOSE PHTHALATE; INSULIN; NANOPARTICLE; PEPTIDE; POLYACRYLIC ACID; SALCATONIN; TECHNETIUM 99M;

ANAPHYLAXIS; ANTIBODY DETECTION; BLOOD ANALYSIS; CELL STRAIN CACO 2; CELL STRAIN HT29; DNA EXTRACTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG RELEASE; GAMMA SCINTIGRAPHY; GENE DELIVERY SYSTEM; GUT ON A CHIP; HISTOLOGY; HUMAN; IMAGING; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; IVIS IMAGING; MEDICAL DEVICE; NONHUMAN; ORAL DRUG ADMINISTRATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; REPORTER GENE; REVIEW; RNA EXTRACTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STOMACH JUICE; STOMACH MUCUS; STOMACH PH; TIGHT JUNCTION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CELL LINE; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG EVALUATION, PRECLINICAL; GASTROINTESTINAL TRACT; HEMATOLOGIC TESTS; HUMANS; IMMUNOASSAY; MODELS, BIOLOGICAL; NANOPARTICLES; POLYMERASE CHAIN REACTION; RADIONUCLIDE IMAGING;

EID: 84878842456     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.01.003     Document Type: Review

References (90)

1. Cleland J.L., Daugherty A., Mrsny R. Emerging protein delivery methods. Curr. Opin. Biotechnol. 2001, 12:212-219.
2. Jinturkar K.A., Rathi M.N., Misra A. 3 - gene delivery using physical methods. Challenges in Delivery of Therapeutic Genomics and Proteomics 2011, 83-126. Elsevier, London. M. Ambikanandan (Ed.).
3. Wang B., Feng W., Zhu M., Wang Y., Wang M., Gu Y., Ouyang H., Wang H., Li M., Zhao Y., Chai Z., Wang H. Neurotoxicity of low-dose repeatedly intranasal instillation of nano- and submicron-sized ferric oxide particles in mice. J. Nanopart. Res. 2009, 11:41-53.
4. Donnelly R.F., Raj Singh T.R., Woolfson A.D. Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety. Drug Deliv. 2010, 17:187-207.
5. Cui-shuan W., Xue-qing W., Meng M., Ming-guang L., Hua Z., Xuan Z., Jian-cheng W., Tao W., Wen-hui N., Qiang Z. Effects of pH-sensitive nanoparticles prepared with different polymers on the distribution, adhesion and transition of Rhodamine 6G in the gut of rats. J. Microencapsul. 2010, 27:205-217.
6. Sezgin Z., Yuksel N., Baykara T. Investigation of pluronic and PEG-PE micelles as carriers of meso-tetraphenyl porphine for oral administration. Int. J. Pharm. 2007, 332:161-167.
7. Lin Y.-H., Chung C.-K., Chen C.-T., Liang H.-F., Chen S.-C., Sung H.-W. Preparation of nanoparticles composed of chitosan/poly-γ-glutamic acid and evaluation of their permeability through caco-2 cells. Biomacromolecules 2005, 6:1104-1112.
8. Evans D.F., Pye G., Bramley R., Clark A.G., Dyson T.J., Hardcastle J.D. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 1988, 29:1035-1041.
9. O'Neill M.J., Bourre L., Melgar S., O'Driscoll C.M. Intestinal delivery of non-viral gene therapeutics: physiological barriers and preclinical models. Drug Discov. Today 2011, 16:203-218.
10. Yamada T., et al. Textbook of Gastroenterology 2009, Blackwell Publishing Ltd., Hoboken, NJ.
11. Iain C. The mouth, stomach and intestines. Anaesth. Intensive Care Med. 2009, 10:336-338.
12. M. Gregory, Digestive System, in, Clinton Community College. (Access date was March 14, 2012.).
13. Allen A., Shary D. The structure and function of gastric mucus. Gut 1972, 13:666-672.
14. Lai S.K., Wang Y.-Y., Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 2009, 61:158-171.
15. Creamer B. The turnover of the epithelium of the small intestine. Br. Med. Bull. 1967, 23:226-230.
16. Ensign L.M., Cone R., Hanes J. Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers. Advanced Drug Delivery Reviews 2012.
17. Enslin G.M., Hamman J.H., Kotze A.F. Oral delivery of peptide drugs: barriers and developments. BioDrugs 2005, 19:165+.
18. Pade V., Stavchansky S. Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture model. Pharm. Res. 1997, 14:1210-1215.
19. Borchard G., Lueβen H.L., de Boer A.G., Verhoef J.C., Lehr C.-M., Junginger H.E. The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: Effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro. J. Control. Release 1996, 39:131-138.
20. Smith J., Wood E., Dornish M. Effect of chitosan on epithelial cell tight junctions. Pharm. Res. 2004, 21:43-49.
21. Ranaldi G., Marigliano I., Vespignani I., Perozzi G., Sambuy Y. The effect of chitosan and other polycations on tight junction permeability in the human intestinal Caco-2 cell line. J. Nutr. Biochem. 2002, 13:157-167.
22. Garnett M.C., Kallinteri P. Nanomedicines and nanotoxicology: some physiological principles. Occup. Med. 2006, 56:307-311.
23. Schneeberger E.E., Lynch R.D. The tight junction: a multifunctional complex. Am. J. Physiol. Cell Physiol. 2004, 286:C1213-C1228.
24. Lozier J.N., Yankaskas J.R., Ramsey W.J., Chen L., Berschneider H., Morgan R.A. Gut epithelial cells as targets for gene therapy of hemophilia. Hum. Gene Ther. 1997, 8:1481-1490.
25. Rieux A.d., Ragnarsson E.G.E., Gullberg E., Préat V., Schneider Y.-J., Artursson P. Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. European Journal of Pharmaceutical Sciences 2005, 455-465.
26. Hase K., Kawano K., Nochi T., Pontes G.S., Fukuda S., Ebisawa M., Kadokura K., Tobe T., Fujimura Y., Kawano S., Yabashi A., Waguri S., Nakato G., Kimura S., Murakami T., Iimura M., Hamura K., Fukuoka S.-I., Lowe A.W., Itoh K., Kiyono H., Ohno H. Uptake through glycoprotein 2 of FimH+bacteria by M cells initiates mucosal immune response. Nature 2009, 462:226-230.
27. Ramesan R.M., Sharma C.P. Challenges and advances in nanoparticle-based oral insulin delivery. Expert Rev. Med. Devices 2009, 6:665+.
28. Kawashima Y., Yamamoto H., Takeuchi H., Kuno Y. Mucoadhesive DL-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharm. Dev. Technol. 2000, 5:77.
29. Lamprecht A.e.a. Low molecular weight heparin nanoparticles: mucoadhesion and behaviour in Caco-2 cells. Nanotechnology 2006, 17:3673-3680.
30. Adler A.F., Leong K.W. Emerging links between surface nanotechnology and endocytosis: Impact on nonviral gene delivery. Nano Today 2010, 5:553-569.
31. Trapp S., Rosania G.R., Horobin R.W., Kornhuber J. Quantitative modeling of selective lysosomal targeting for drug design. Eur. Biophys. J. 2008, 37:1317-1328.
32. Glangchai L.C., Caldorera-Moore M., Shi L., Roy K. Nanoimprint lithography based fabrication of shape-specific, enzymatically-triggered smart nanoparticles. J. Control. Release 2008, 125:263-272.
33. Wu C.S., Wang X.Q., Meng M., Li M.G., Zhang H., Zhang X., Wang J.C., Wu T., Nie W.H., Zhang Q. Effects of pH-sensitive nanoparticles prepared with different polymers on the distribution, adhesion and transition of Rhodamine 6G in the gut of rats. J. Microencapsul. 2010, 27:205-217.
34. Tahara K., Samura S., Tsuji K., Yamamoto H., Tsukada Y., Bando Y., Tsujimoto H., Morishita R., Kawashima Y. Oral nuclear factor-κB decoy oligonucleotides delivery system with chitosan modified poly(d, l-lactide-co-glycolide) nanospheres for inflammatory bowel disease. Biomaterials 2011, 32:870-878.
35. Fievez V., Plapied L., des Rieux A., Pourcelle V., Freichels H., Wascotte V., Vanderhaeghen M.-L., JerÔme C., Vanderplasschen A., Marchand-Brynaert J., Schneider Y.-J., Préat V. Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination. Eur. J. Pharm. Biopharm. 2009, 73:16-24.
36. Hossen M.N., Kajimoto K., Akita H., Hyodo M., Harashima H. Vascular-targeted nanotherapy for obesity: Unexpected passive targeting mechanism to obese fat for the enhancement of active drug delivery. J. Control. Release 2012, 163:101-110.
37. Vllasaliu D., Alexander C., Garnett M., Eaton M., Stolnik S. Fc-mediated transport of nanoparticles across airway epithelial cell layers. J. Control. Release 2012, 158:479-486.
38. Kim J.-H., Kim Y.-S., Park K., Kang E., Lee S., Nam H.Y., Kim K., Park J.H., Chi D.Y., Park R.-W., Kim I.-S., Choi K., Chan Kwon I. Self-assembled glycol chitosan nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy. Biomaterials 2008, 29:1920-1930.
39. C.Incorporated Transwell® Permeable Supports Selection and Use Guide, in, USA 2010.
40. Plapied L., Vandermeulen G., Vroman B., Préat V., des Rieux A. Bioadhesive nanoparticles of fungal chitosan for oral DNA delivery. Int. J. Pharm. 2010, 398:210-218.
41. Mittal G., Carswell H., Brett R., Currie S., Kumar M.N.V.R. Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer's pathology. J. Control. Release 2011, 150:220-228.
42. Trapani A., Lopedota A., Franco M., Cioffi N., Ieva E., Garcia-Fuentes M., Alonso M.J. A comparative study of chitosan and chitosan/cyclodextrin nanoparticles as potential carriers for the oral delivery of small peptides. Eur. J. Pharm. Biopharm. 2010, 75:26-32.
43. Cui F., Shi K., Zhang L., Tao A., Kawashima Y. Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. J. Control. Release 2006, 114:242-250.
44. Lin Y.-H., Sonaje K., Lin K.M., Juang J.-H., Mi F.-L., Yang H.-W., Sung H.-W. Multi-ion-crosslinked nanoparticles with pH-responsive characteristics for oral delivery of protein drugs. J. Control. Release 2008, 132:141-149.
45. Patel N., Forbes B., Eskola S., Murray J. Use of simulated intestinal fluids with Caco-2 cells and rat ileum. Drug Dev. Ind. Pharm. 2006, 32:151-161.
46. Ingels F., Deferme S., Destexhe E., Oth M., Van den Mooter G., Augustijns P. Simulated intestinal fluid as transport medium in the Caco-2 cell culture model. Int. J. Pharm. 2002, 232:183-192.
47. Sahana D.K., Mittal G., Bhardwaj V., Kumar M.N.V.R. PLGA nanoparticles for oral delivery of hydrophobic drugs: Influence of organic solvent on nanoparticle formation and release behavior In Vitro and In Vivo using estradiol as a model drug. J. Pharm. Sci. 2008, 97:1530-1542.
48. Italia J.L., Bhatt D.K., Bhardwaj V., Tikoo K., Kumar M.N.V.R. PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral®. J. Control. Release 2007, 119:197-206.
49. Avgoustakis K., Beletsi A., Panagi Z., Klepetsanis P., Karydas A.G., Ithakissios D.S. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J. Control. Release 2002, 79:123-135.
50. Behrens I., Stenberg P., Artursson P., Kissel T. Transport of lipophilic drug molecules in a new mucus-secreting cell culture model based on HT29-MTX cells. Pharm. Res. 2001, 18:1138-1145.
51. Dong Y., Feng S.-S. Poly(d, l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005, 26:6068-6076.
52. Mi F.-L., Wu Y.-Y., Lin Y.-H., Sonaje K., Ho Y.-C., Chen C.-T., Juang J.-H., Sung H.-W. Oral delivery of peptide drugs using nanoparticles self-assembled by poly(γ-glutamic acid) and a chitosan derivative functionalized by trimethylation. Bioconjug. Chem. 2008, 19:1248-1255.
53. McClean S., Prosser E., Meehan E., O'Malley D., Clarke N., Ramtoola Z., Brayden D. Binding and uptake of biodegradable poly-dl-lactide micro- and nanoparticles in intestinal epithelia. Eur. J. Pharm. Sci. 1998, 6:153-163.
54. Artursson P., Palm K., Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 2001, 46:27-43.
55. Sutton S.C., Forbes A.E., Cargill R., Hochman J.H., LeCluyse E.L. Simultaneous in vitro measurement of intestinal tissue permeability and transepithelial electrical resistance (TEER) using sweetana-grass diffusion cells. Pharm. Res. 1992, 9:316-319.
56. Narai A., Arai S., Shimizu M. Rapid decrease in transepithelial electrical resistance of human intestinal Caco-2 cell monolayers by cytotoxic membrane perturbents. Toxicol. Vitr. 1997, 11:347-354.
57. Walter E., Janich S., Roessler B.J., Hilfinger J.M., Amidon G.L. HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans. J. Pharm. Sci. 1996, 85:1070-1076.
58. Mahler G.J., Shuler M.L., Glahn R.P. Characterization of Caco-2 and HT29-MTX cocultures in an in vitro digestion/cell culture model used to predict iron bioavailability. J. Nutr. Biochem. 2009, 20:494-502.
59. des Rieux A., Fievez V., Théate I., Mast J., Préat V., Schneider Y.-J. An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells. Eur. J. Pharm. Sci. 2007, 30:380-391.
60. E. Gullberg, M. Leonard, J. Karlsson, A.M. Hopkins, D. Brayden, A.W. Baird, P. Artursson, Expression of Specific Markers and Particle Transport in a New Human Intestinal M-Cell Model: Volume 279, Number 3 (2000), pages 808-813, Biochemical and Biophysical Research Communications, 281 (2001) 1063.
61. Kernéis S., Bogdanova A., Kraehenbuhl J.-P., Pringault E. Conversion by Peyer's patch lymphocytes of human enterocytes into M Cells that transport bacteria. Science 1997, 277:949-952.
62. Kim H.J., Huh D., Hamilton G., Ingber D.E. Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. Lab Chip 2012, 12:2165-2174.
63. Lehr C.M., Bouwstra J.A., Kok W., De Boer A.G., Tukker J.J., Verhoef J.C., Breimer D.D., Junginger H.E. Effects of the mucoadhesive polymer polycarbophil on the intestinal absorption of a peptide drug in the rat. J. Pharm. Pharmacol. 1992, 44:402-407.
64. Lueßen H.L., Rentel C.O., Kotzé A.F., Lehr C.M., de Boer A.G., Verhoef J.C., Junginger H.E. Mucoadhesive polymers in peroral peptide drug delivery. IV. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro. J. Control. Release 1997, 45:15-23.
65. Chakraborty S., Shukla D., Mishra B., Singh S. Lipid - an emerging platform for oral delivery of drugs with poor bioavailability. Eur. J. Pharm. Biopharm. 2009, 73:1-15.
66. Cryan S.-A., O'Driscoll C.M. Mechanistic studies on nonviral gene delivery to the intestine using in vitro differentiated cell culture models and an in vivo rat intestinal loop. Pharm. Res. 2003, 20:569-575.
67. Desai M.P., Labhasetwar V., Amidon G.L., Levy R.J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 1996, 13:1838-1845.
68. Lv H., Wang G., Wu X., Xie L., Huang C., Li H., Liang Y., Hao H., Sun J. Transport characteristics of ginkgolide B by Caco-2 cells and examination of ginkgolide B oral absorption potential using rat in situ intestinal loop method. Int. J. Pharm. 2008, 351:31-35.
69. Damgé C., Maincent P., Ubrich N. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J. Control. Release 2007, 117:163-170.
70. Pappo J., Ermak T.H. Uptake and translocation of fluorescent latex particles by rabbit Peyer's patch follicle epithelium: a quantitative model for M cell uptake. Clin. Exp. Immunol. 1989, 76:144-148.
71. Florence D. Evaluation of nano- and microparticle uptake by the gastrointestinal tract. Adv. Drug Deliv. Rev. 1998, 34:221-233.
72. Chen J., Yang W.L., Li G., Qian J., Xue J.L., Fu S.K., Lu D.R. Transfection of mEpo gene to intestinal epithelium in vivo mediated by oral delivery of chitosan-DNA nanoparticles. World J. Gastroenterol. 2004, 10:112-116.
73. Ma W., Rogers K., Zbar B., Schmidt L. Effects of different fixatives on β-galactosidase activity. J. Histochem. Cytochem. 2002, 50:1421-1424.
74. Bowman K., Sarkar R., Raut S., Leong K.W. Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles. J. Control. Release 2008, 132:252-259.
75. Dhadwar S.S., Kiernan J., Wen J., Hortelano G. Repeated oral administration of chitosan/DNA nanoparticles delivers functional FVIII with the absence of antibodies in hemophilia A mice. J. Thromb. Haemost. 2010, 8:2743-2750.
76. Roy K., Mao H.Q., Huang S.K., Leong K.W. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med. 1999, 5:387-391.
77. Verma D., Moghimi B., LoDuca P.A., Singh H.D., Hoffman B.E., Herzog R.W., Daniell H. Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice. Proc. Natl. Acad. Sci. 2010, 107:7101-7106.
78. Sakuma S., Suzuki N., Kikuchi H., Hiwatari K.-i., Arikawa K., Kishida A., Akashi M. Oral peptide delivery using nanoparticles composed of novel graft copolymers having hydrophobic backbone and hydrophilic branches. Int. J. Pharm. 1997, 149:93-106.
79. McDowell A., Nicoll J.J., McLeod B.J., Tucker I.G., Davies N.M. Gastrointestinal transit in the common brushtail possum measured by gamma scintigraphy. Int. J. Pharm. 2005, 302:125-132.
80. Wilding I.R., Coupe A.J., Davis S.S. The role of γ-scintigraphy in oral drug delivery. Adv. Drug Deliv. Rev. 2001, 46:103-124.
81. Parmentier J., Thewes B., Gropp F., Fricker G. Oral peptide delivery by tetraether lipid liposomes. Int. J. Pharm. 2011, 415:150-157.
82. Theodorakis M.C. External scintigraphy in measuring rate of gastric-emptying in beagles. Am. J. Physiol. 1980, 239:G39-G43.
83. Goodman K., Hodges L.A., Band J., Stevens H.N.E., Weitschies W., Wilson C.G. Assessing gastrointestinal motility and disintegration profiles of magnetic tablets by a novel magnetic imaging device and gamma scintigraphy. Eur. J. Pharm. Biopharm. 2010, 74:84-92.
84. Reba R.C., Goodenough David J., Davidson Harold F. Diagnostic imaging in medicine 1983, Martinus Nijhoff Publishers, The Netherlands. R.C. Reba (Ed.).
85. Ollinger J.M., Fessler J.A. Positron-emission tomography. Signal Proc. Mag. IEEE 1997, 14:43-55.
86. Sonaje K., Lin K.-J., Wey S.-P., Lin C.-K., Yeh T.-H., Nguyen H.-N., Hsu C.-W., Yen T.-C., Juang J.-H., Sung H.-W. Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: oral delivery using pH-Responsive nanoparticles vs. subcutaneous injection. Biomaterials 2010, 31:6849-6858.
87. Sonaje K., Lin K.-J., Tseng M.T., Wey S.-P., Su F.-Y., Chuang E.-Y., Hsu C.-W., Chen C.-T., Sung H.-W. Effects of chitosan-nanoparticle-mediated tight junction opening on the oral absorption of endotoxins. Biomaterials 2011, 32:8712-8721.
88. Chen C.-C., Tsai T.-H., Huang Z.-R., Fang J.-Y. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur. J. Pharm. Biopharm. 2010, 74:474-482.
89. Lee C.M., Jeong H.J., Yun K.N., Kim D.W., Sohn M.H., Lee J.K., Jeong J., Lim S.T. Optical imaging to trace near infrared fluorescent zinc oxide nanoparticles following oral exposure. Int. J. Nanomedicine 2012, 7:3203-3209.
90. Säkkinen M., Marvola J., Kanerva H., Lindevall K., Ahonen A., Marvola M. Are chitosan formulations mucoadhesive in the human small intestine? An evaluation based on gamma scintigraphy. Int. J. Pharm. 2006, 307:285-291.